Skip to main content
Clinical Trials/IRCT20130812014333N147
IRCT20130812014333N147
Recruiting
Phase 3

Comparative assessment of the efficacy and safety of addon treatment with Sofosbuvir-Daclatasvir”, Lithium”,and Trifluoprazine” to standard of care in three groups of patients with COVID-19

Kermanshah University of Medical Sciences0 sites80 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Kermanshah University of Medical Sciences
Enrollment
80
Status
Recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age over 18 years
  • Absolute lymphocyte count \<1100 / ML or SaO2 \<93

Exclusion Criteria

  • Pregnancy or breast\-feeding
  • The physician's decision that the trial is not in the patient's interest
  • Any circumstances that do not allow the treatment protocol to be followed easily
  • A history of known allergies to Sofosbuvir\-Velp, Trifluoprazine, Lithium and Trihexyphenidyl
  • Drugs that their concomitant use with standard treatment or Sofosbuvir\-Velpatasvir, Trifluoprazine, Lithium, and Trihexyphenidyl are contraindicated and can not be discontinued.

Outcomes

Primary Outcomes

Not specified

Similar Trials